Difference between revisions of "Cytarabine (Ara-C)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (moved Cytarabine (Ara-C) to Cytarabine (Cytosar) over redirect)
Line 1: Line 1:
 +
Also known as Ara-C.
 
==General information==
 
==General information==
 
Class/mechanism: Pyrimidine analog, mimics cytosine.  Converted intracellularly into cytarabine-5-triphosphate (ara-CTP).  Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.hospira.com/_docs/Cytarabine%20483176-PROMOWEB.pdf Cytarabine (Cytosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cytarabine.pdf Cytarabine (Cytosar) package insert (locally hosted backup)]</ref>
 
Class/mechanism: Pyrimidine analog, mimics cytosine.  Converted intracellularly into cytarabine-5-triphosphate (ara-CTP).  Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.<ref name="insert">[http://www.hospira.com/_docs/Cytarabine%20483176-PROMOWEB.pdf Cytarabine (Cytosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/cytarabine.pdf Cytarabine (Cytosar) package insert (locally hosted backup)]</ref>

Revision as of 04:59, 11 December 2011

Also known as Ara-C.

General information

Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2]
Route: IV, IT, SC
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].

Patient drug information

Regimens

Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)

References